Jade Biosciences, Inc. Restructuring and Related Cost, Incurred Cost
Jade Biosciences, Inc. (JBIO) reported Restructuring and Related Cost, Incurred Cost of $6.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2025-04-25
- Jade Biosciences, Inc. restructuring and related cost, incurred cost for the quarter ending 2024-12-31 was $300.00K.
- Jade Biosciences, Inc. restructuring and related cost, incurred cost for the quarter ending 2024-09-30 was -$100.00K.
- Jade Biosciences, Inc. restructuring and related cost, incurred cost for fiscal 2024 was $6.70M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $200.00K derived: sum of 2 quarters · filed 2025-03-27 | $6.70M 10-K · filed 2025-03-27 | |
| 2024-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.40M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $6.50M 10-Q · filed 2025-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |